ArticleClinical medicine insights. Case reports2023
Delayed Anaphylaxis to Intravenous Colistin in a Critically Ill Cancer Patient: A Case Report.
Article in Clinical medicine insights. Case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anaphylaxis is an acute, life-threatening, multi-system syndrome that has been reported with a wide range of medications. Though anaphylaxis usually has a rapid onset, we describe a patient who developed anaphylaxis to intravenous colistin after 28 days of daily administration. Case presentation: A 20 years-old Caucasian male patient, with a history of relapsed acute myeloid leukemia, was transferred from the medical floor to our intensive care unit with septic shock. The source of infection was presumed to be a recto-cecal abscess and arm cellulitis. Cultures were positive for extended spectrum beta-lactamase (ESBL) and carbapenem-resistant enterobacteriaceae (CRE) Conclusion: This case highlights the importance of being aware of delayed serious reactions that may occur several weeks after initiation of drug therapy. In addition, successful re-initiation may not necessarily rule out the recurrence of such reactions and therefore close monitoring is crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.